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1. Introduction  
Estrogens play a key role in multiple physiological functions in women. They have 
important actions on bone and lipid metabolism, cardiovascular function, and diffuse effects 
on other target organs. Estrogens have important roles in cognitive function and influence 
psychological well-being in women, in development and maintenance of the reproductive 
system in the female (Gustafsson, 2003). The most potent estrogens are 17ǃ-estradiol 1, 
estrone 2 and estriol 3 may have tissue-specific roles (Gruber & Huber, 1999).  
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In female body estrogens are formed in ovaries, and as result the menopause is associated 
with an increased risk of the development of cardiovascular diseases, osteoporosis and 
many other diseases. In postmenopausal women, many of these functions (positive effect on 
prevention of osteoporosis and improved serum profile enhanced by the use of estrogen 
replacement therapy) are achievement. The positive action of estrogens on prophylactic and 
treatment of osteoporosis has been proved undoubtedly, however other clinical data are 
considered as contradictory (Davison & Davis, 2003). Moreover, during the use of estrogens 
for HRT the number of strokes is increasing (Bushnell, 2005). It was absolutely unexpected 
because the adverse effect has been observed in experiments on animals. It was also found 
that during long-term using of estrogens the risk of some oncological diseases is increasing 
(Beral, 2003; Beral et al., 2005).  Other side effects, which we discuss later, also indicate the 
necessity for the search of new safe estrogen analogues with the improved biological 
properties.   
Firstly we consider the results in these directions, and then we discuss the main advantages 
of the creation of agents with directed biological action, which are perspective for HRT, for 
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the treatment of oncological estrogen-sensitive diseases, cardio-vascular system, 
osteoporosis, neuroendocrinal diseases. The division of agents on such groups has relative 
character, because the activity of steroid estrogens has multifunctional character and one 
compound may be effectively used in various fields. This is a main reason why modified 
steroid estrogens have the advantage in comparison with huge number of heterocyclic 
compounds, having more selective action.  
Obviously that most perspective search of such compounds is done on the basis of 
knowledge about estrogen action mechanism, particularity of its structure and metabolism.  
 Several authors consider that main fast non genomic effects of estrogens are mediated by 
their membrane receptors (Levin, 2002; Sak & Evaraus, 2004). Experimental data about the 
identity of nuclear and membrane ERǂ in MCF7 cell are presented in the publication 
(Pedram et al., 2009). Obviously, ligand specificity may be significantly different. 
Mechanisms of membrane receptors action are still unclear, very often it is not proved that 
one or another effect is mediated by namely this group of receptors (Warner & Gustafsson, 
2006). The absence of data about ligand specificity to membrane receptors does not allow to 
plan the synthesis of modified steroids with selective action, especially taking into account 
that their activity is realizing on many ways. During the consideration of osteoprotective 
action of estrogens and its influence on processes of cardio-vascular system we restrict 
ourselves to state the facts, because the decision concerning the synthesis of potential agents 
is usually reached on the analogy with known compounds.  
2. Genomic actions of estrogens 
The genomic effects of steroid estrogens are mediated through two subtypes of nuclear - 
and ǃ-receptors (ER and ERǃ). In mid 1980s. studies on the cloning of DNA encoding the 
steroid estrogen receptors were initiated (Walter et al., 1986; Green, G.L. et al., 1986; Koike 
et al., 1987). These studies led to the determination of their primary structure. Later they 
were assigned to ERǂ. In 1996, a number researchers discovered new members of the 
superfamily of nuclear estrogen receptors in rat prostate and ovaries (Kuipper et al, 1996) in 
human and mouse (Mosselman et al., 1996; Tremblay et al., 1997) and named it ERǃ. Very 
soon the complete amino acid sequence of human ERǃ (hERǃ) was determinated (Ogawa et 
al., 1998). It was established that ERǃ is significantly shorter than ERǂ. The comparison of 
amino acid sequences of these receptors and the investigation of affinity of various ligands 
to mutant forms of receptors allowed to establish that these receptors have 6 domains.   
The N-terminal domains (A/B) have variable length and amino acid sequences. Usually, 
they exhibit a hormone-independent transactivation function (AF-1) that interacts with the 
elements of the transcription machinery and activate genes in target organs (Tzukerman et 
al., 1994). Domain C is responsible for the DNA recognition and receptor dimerization. This 
is a DNA-binding region, consisting approximately 50 amino acids. Domain E (HBD) 
contains approximately 250 amino acids and ensures the binding of hormones. This domain 
is the «hinge» - after the binding of ligand with receptors the following conformational 
rearrangement takes place with the participation of domain D. Clone 29 protein is highly 
homologous to rat ER, particularly in DNA-binding domain (95%) and ligand-binding 
domain (55%) (Kuipper et al., 1996). High degree of conservation of DNA-binding domain 
(96%) and ligand-binding domain (58%) was registered by other authors (Mosselman et al., 
1996).  
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Ligand-independent transactivational function AF1 is in zone А/В of both sub-types of 
receptors, zone E/F of -receptor of estrogens has additional ligand-independent activation 
function (Tora et al., 1989). ER has ligand-dependent trans-activation function AF-2.  
Without ligand estrogen receptors are in complexes with heat shock proteins (Hsp90, 
Hsp70, Hsp56, Hsp60, Hsp48, Hsp23), this binding takes place in domain ǿ. Probably, being 
in complexes with heat shock proteins estrogens are protected against the action of 
proteases. After binding its ligand conformational rearrangement of LBD of nuclear receptor 
and dissociation of complexes ER – heat shock proteins takes place. Except of the potential 
possibility to activate transcription, this rearrangement causes the change of topography of 
receptor regions, sensitive to proteolysis (Ramsey & Klinge, 2001). Phosphorylation of 
estrogen receptors is observed after their binding with hormone (Kato et al., 1995) that 
enhances the binding.   
Transformed receptor forms dimers and in this form binds with DNA and may activate the 
transcription. Effective dimerization of ER requires a weak constitutive activity of 
sequences in domain C (Kumar & Chambon, 1988). It is necessary to note, that AF1 and AF2 
exhibit relatively weak activity, whereas the maximum of transcription induction is 
observed when they act together (Tora et al., 1989; Pham et al., 1992). From other side, in 
some cases the activation of AF-1 is enough to activate the transcription. Thus, 4-
hydroxytamoxifen 4 is unable to induce AF-2 activity, but it is a strong agonist in cellular 
and promoter context where AF-1 is effective transcriptional activator (Berry et al., 1990). 
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Transcriptional process is modulated by receptors’ ligands and various co-regulators 
(Cheskis et al., 1997; An et al., 1999; 2001; Tcherepanova et al., 2000; Wong et al., 2001; Liu, 
J. et al., 2003; Bai & Gugière, 2003; Xu & Li, 2003). Conformation of ER changes upon 
interaction with coactivator proteins (Tamrazi et al., 2005), as result the activity of one 
ligand may change in depending on cell nature. Thus, tamoxifen 5 and raloxifene 6 are 
agonists of estradiol in cardiovascular system, whereas they show antagonistic properties in 
breast and endometrium (Jordan, 2007). Many others SERMs have similar properties.  
Nowadays more 10 estrogen receptor-ǃ isoforms are known, which have been identified 
starting from 2000 (Lu et al., 2000).  
To study the roles of each receptor in vivo, a series of the mice were generated lacking either 
a functional ER and ERǃ or both (ERKO, ǃERKO, ǃERKO) (Emmel & Korach, 2001).  
ERǃ may modulate the functions of ER, if these receptors are in the same cells (Matthews 
et al., 2006). It became crucial during the diagnostics and the treatment of oncological 
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diseases (Leygue et al., 1998; Pujol et al., 1998; Hall & McDonnel, 1999; Lazennec et al., 
2001; Monroe et al., 2005). Compounds having the preferential binding to ERǃ have great 
perspectives to be used for the treatment of autoimmune diseases, prostate disease, 
depression and ovulation disorders (Gustafsson, 2005). The noted above is the evidence for 
actuality of the search for modulators with preferable affinity to ER or ERǃ.  
Obviously, determination of complexes structure of estrogen receptors with various ligands 
with known biological properties was supposed to contribute to the development of models 
for mechanisms of estrogens action and understanding of the connection between structure 
and hormonal activity of ligands and thus to solve the abovementioned problem. 
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X-rays data of ligand-binding domain of ER with estradiol 1 and raloxifene 6 (Brzozowski 
et al., 1997), 4-hydroxytamoxifen 4 and diethylstilbestrole 7 (Shiau et al., 1998), and ligand-
binding domain of ER with raloxifene 6 and genistein 8 (Pike et al., 1999) have been 
obtained. Estradiol 1 and diethylstilbestrol 7 are full agonists to ER and ER, 4-
hydroxytamoxifen 4, raloxifene 6, and genistein 8 are agonists/antagonists. Interestingly, 
synthetic compounds of type 9 bind with ER as effectively as genistein 8 (Miller et al., 
2003). Removal of ligands 1, 4, 6, 7, 8 from its complexes in crystal with LBD of ER and 
ERǃ, docking of other potential ligands and the following optimization of its position in 
complex and binding energy by molecular modeling methods allow to evaluate the 
properties of new compounds independently from their belonging to steroid series. Some 
vagueness of evaluation of affinity to receptors is connected with the fact that the X-Ray 
data for complexes with different ligands are obtained only with LBD, but not with full-
length receptors.  
The last of utmost importance, because during the realization of transcriptional action the 
formation of complexes between the DNA binding domain of estrogen receptors and 
estrogen response element (ERE) of duplex DNA is necessary, which requires the exact 
disposition of these elements of structure. Earlier structure of the DNA-binding domain of 
the ER has been investigated (Schwabe et al., 1990), however three-dimensional model of 
the DNA binding domain of ER was proposed significantly later (Deegan et al., 2010). On 
account of the above mentioned the differences in RBA values of model compounds to full-
length receptor and to its LBD could be significant. Thus, the affinity of (5S,11S)-5,11-
diethyl-5,6,11,12-tetrahydrochrisene-2,8-diol 9 to full-length ERǃ is in 10 times higher, than 
to its LBD (Meyers et al., 1999).  
The results of quantum chemical calculations of ligand-receptor complexes allowed to 
synthesize a huge number of compounds having more then in 100-times higher effective 
binding to -ER in comparison to -ER (Manas et al., 2004). 
There are other ways for evaluation of properties of new compounds. For example some of 
them are traditional QSAR methods (Gantchev et al., 1994; Tong et. al., 1997; Wiese et. al, 
1997; Azzaoui et al., 1998; Gao et al., 1999; Wurtz et al., 1998; Sippl, 2002; Klopman & 
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Chakravarti, 2003; Wolohan & Reichert, 2004; Pasha et al., 2005). In spite of the fact that 
such approaches have moderate predicted force, they do not provide the deeper 
understanding of estrogen action mechanism. From our point of view, using the multimodal 
approach, based on the application of methods of comparative molecular field analysis and 
binding energy calculations is most perspective (Wolohan & Reichert, 2004).   
The knowledge about conformational mobility of different groups of potential ligands of 
ERs has great importance (Kym et al., 1993; Grese et al., 1998; Selivanov & Shavva, 2002). 
These data have interest in connection with data about modeling of conformations of ligand-
receptor complexes (Kraichely et al., 2000; Egner et al., 2001) and conformational dynamic 
of ERs (Celic et al., 2007).  
Let’s consider the examples of successful searching of modified estrogens which have 
selective binding affinity to hERǂ or hERǃ (Hillisch et al, 2004).  
Structure analysis of LBD of these receptors shows that the nearest surrounding of bound 
estradiol in these receptors differs from each other on two amino acid residues: Leu384 and 
Met421 in ERǂ are substituted by Met336 and Ile373 in ERǃ. Volumes of side chains of these 
amino acid residues are 85.9 Ǻ (Met), 82.6 Ǻ (Leu) and 82.3 Ǻ (Ile). It was predicted that the 
increased flexibility of the linear Met side chain would allow larger substituent to be 
accommodated. Met336 ERǃ is situated closely to position 8ǃ, and the introduction of small 
lipophilic substituent into this position must lead to the increasing of RBA of modified 
analogue to ERǃ. Ǻet421 of ERǂ is at region of D-ring, and analogue with substituent at 
positions 16ǂ and/or 17ǂ will have the increased affinity to ERǂ.  
Experiments have proved the stated predictions. As reference compounds steroids 10 and 12 
have been used. First one has selectivity hERǂ/hERǃ is 20, and for second one this value 
hERǃ/hERǂ is 22.5. Modified analogues 11 and 13 have the mentioned ratios as 70 and 180 
correspondingly.  
Unfortunately, there is no correlation between RBA values for hERǂ and hERǃ with values 
obtained in the experiments with the corresponding receptors of animals.  
In some cases the ratio between these values are opposite (Hillisch et al., 2004). 
The investigation of RBA for 71 compounds (mainly, metabolites of estrogens) to hERǂ and 
hERǃ have shown that the differences in experimental values are not more then one order 
(Zhu et al., 2006).   
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The introduction of relatively small linear substituents (4-5 carbon atoms) at position 11 of 
steroid skeleton may lead to the appearance of antagonistic activity to ER at agonistic 
properties to ER (steroids 14 and 15), whereas analogue 16 is agonist to both receptors 
(Loosen, 1999).     
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Steroids with small substituents at position 11 without aromatic ring possess significantly 
higher affinity and transcriptional activity of ER (Loosen еt al., 2000), for example, 
analogues 17-19 have been found.  
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Finally, there are compounds, which fully block the binding of estradiol 1 with known ERs, 
for example steroids 20-23 (Jordan, 2003). A number of compounds with large substituents 
at ǿ-7 () and ǿ-11 () have been synthesized, such analogues are of great interest for the 
treatment of estrogen-dependent oncological diseases and hormones imbalance, caused by 
the increased formation of estrogens in the body.        
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3. Carcinogenicity causes of ER ligands 
The establishment of at least major reasons of carcinogenicity of estrogens, their 
agonists/antagonists has significant importance, since this understandings lies in the 
fundament of the creation of medications with the improved properties.  
At the present time two main types of carcinogenesis are known - promotive and genotoxic 
(mutagenic), action of them may add up. Existence of the fist one is confirmed by well-
known facts of tumor formation under the estrogen action (Russo et al., 2002) and 
promotion of tumor induction under the action of various agents, for example, nitroso-
butylurea (Sumi et al., 1984). The same results have been obtained in other models. For 
example, 17ǂ-ethynylestradiol 24 enhances the tumor formation in rat males under the 
action of diethylnitrosamine (Yoshida & Fukunishi, 1981). Estradiol increased dysplasia of 
breast on androgenized rats, induced by 7,12-dimethylbenz[a]anthracene.  
The explanation of this negative influence of estrogens is quite clear – when in active state 
the cells are vulnerable to attacks by reactive compounds.   
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Lately using 2-fluoroestradiol 25 as an example it was shown that there is no correlation 
between carcinogenicity and hormonal action of estrogens (Liehr, 1983). It is important that 
17-ethynylestradiol 24 possesses high hormonal activity and lowered carcinogenicity (Li, 
J.J. et al., 1995). These investigations (and earlier ones) became the basis for searching of 
other mechanisms of estrogens’ carcinogenicity. 
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Specifically, it was established that estrogen metabolites may covalently bind with 
hamster microsomic proteins, and this process is inhibited by ascorbinic and cathehol-O-
methytransferase action (Haaf et al., 1987). Therefore authors proposed that «active» 
metabolites are о-quinones, which possess heightened reactivity. In next 20 years it was 
clarified that the hydroxylation of estrogens in the body leads to the formation of 2- or 4-
hydroxyestrogens of types 26 and 27, which then converted to о-quinones of type 28 and 
29 (Liehr et al., 1995; 1996; Bolton et al., 1998; Bolton, 2002; Bolton & Thatcher, 2008; 
Zhang, F. et al., 1999; Liu, X. et al., 2002; Zhang, Q. et al., 2008). Irreversible depurination 
of DNA that could not be regenerated by reparases may take place under the action of o-
quinones. Compounds of types 31 and 32 are possible depurination products. Quinones of 
type 28 do not cause the damage of DNA. It is assumed that the reason of this is their 
heightened reactivity; therefore they may be deactivated before their migration into cell 
nucleus.  
From our point of view one of possible variants for the decreasing of estrogens’ 
carcinogenicity is the introduction of a substituent in the position 1, which blocks the 
interaction with DNA and thus prevents its depurination. In the case when compounds with 
substituent at position 1 will lead to decreasing of estrogenic activity, such modification (in 
dependence from the task) will be very perspective.   
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It is also known that metabolites with hydroxyl group at C-6 of types 33 and 34 may have 
carcinogenic properties (Itoh et al., 1998). Thus, compounds which can not be hydroxylated 
at position 6 are perspective potential candidates for synthesis and further investigations.  
Another metabolite of estrogens - 16-hydroxyestrone 35 is also considered as inductor of 
tumors’ formation (Lewis et al., 2001; Seeger et al., 2006). Hydroxylation of estrone at 
position 16 is one of main directions of estrogen metabolism, which is elevated in women 
with high risk of breast cancer, as well with other oncological diseases. Estriol 3 content is 
informative as well: there is the correlation between breast tumors’ development in mice 
(Lewis et al., 2001).  
Products of hydroxylation of equilenin and equilin also possess carcinogenic properties 
(Zhang, F. et al., 1999; Shen et al., 1997). Corresponding quinones may damage DNA, and 
the investigation of this class of compounds with substituent at position 4 is of a great 
importance. Authors concluded that 4-fluoroequilenin derivatives 36 are promising 
alternatives to traditional estrogen replacement therapy due to their similar estrogenic 
properties with less overall toxicity (Liu, X. et al., 2003).  
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The hydroxylation of selective modulators of ERs and the following reaction products 
transformations may cause DNA depurination that leads to carcinogenicity of drugs. It was 
shown on the example of the formation of -hydroxytamoxifen 37 and its possible 
transformation into compounds of type 38  (Jordan, 2007).   
It is not surprising that during last years the efforts are directed to the methods of steroid 
estrogen level determination, because the exact value of their content in various tissues helps to 
diagnose differentially various hormone-sensitive diseases (Arai et al., 2010; Blair et al., 2010).  
4. Inhibition of estrone formation in the body  
It is known that about two thirds of all the breast cancers occur in postmenopausal women, 
when estrogen is no longer synthesized in ovaries. However the estradiol content in 
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estrogen-dependent tumors is significantly higher than in blood plasma and in normal 
tissues on bourdes with tumors. Partly it can be explained by the ability of tumor to accept 
estradiol from the blood (Pasqualini et al., 1996), because estrogen synthesis may be 
enhanced in extragonadal organs. Furthermore, local synthesis of estrogens in tumor may be 
on high level (Pasqualini et al., 1997). In view of the aforesaid it is necessary to consider the 
ways of synthesis of these hormones and understand the influence on the formation of 
reactive estrogens in tumor (scheme).  
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It is well-known, that estrogens are formed in the body from testosterone or androst-4-en-
3,17-dione 39. Aromatization is multistep process, proceeding under the action of enzymes 
of cytochrome Ǿ-450 system. The main steps of aromatization, key stage in estrogen 
formation are considered in many publications (Jordan & Brodie, 2007 and citations herein). 
It is reasonable that the great attention is directed to the search of irreversible inhibitors of 
aromatase.  
Most often the initial investigations are carrying out on human placenta cells, the criterion 
for the evaluation of effectiveness of investigated compounds is value of IC50 
(concentration, at which the inhibition of enzyme activity is 50% from highest possible 
one under experimental conditions). Compounds having IC50 in the range of nanomolar 
concentrations have perspectives to be further investigated. Next step for the evaluation 
of inhibitory activity of perspective compounds is the investigation on animal models, 
and very often the preliminary evaluation of effectiveness is in contrast with data 
obtained in second series. 
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Steroid 41 and 42 properties investigation results could be used as an example (diSalle & 
Robinson, 1990). The IC50 values in the experiments on human placenta cells are 
approximately equal - 42.5±4.3 and 20.3±2.2 nM correspondingly. However, in the 
experiments on rats the values of ED50 (dose, at which the inhibition is 50% from highest 
possible one) are 3.7 and more 100 mg/kg under per os injection. Necessity of compounds 
investigation can be illustrated by huge number of examples in various animal models and 
by methods of steroids introduction into the body. In particular, compound 42 under 
subcutaneous introduction in doses 30 and 150 mg/kg blocks the growth of bearing DMBA-
induced mammary tumors in female rats (Nishino et al., 1989) and after numerous 
investigations is clinically used with the trade name atamestane.   
The main position for attack during demethylation of androst-4-en-3,17-dione is methyl 
group at ǿ-19. Numerous derivatives at ǿ-10 have been synthesized. Among them the most 
effective one is compound 43 with Ki 3 nǺ to human placenta enzyme (Cole & Robinson, 
1990). It comes as no surprise, that this compound is clinically used (Numazava et al., 2005). 
Compounds 44 (Greway et al., 1990) and 45 (Peet et al., 1992) demonstrated good 
properties.  
Detailed search of aromatase inhibitors led to the creation of medications of steroid nature 
for the treatment of oncological diseases in clinic, from them, exemestane 41 and formestane 
46 are also widely known. However clinical application of aromatase inhibitors revealed the 
presence of a number of non-specific toxic side effects: asthenia, nausea, headache etc. 
Certain endocrinological side effects in postmenopausal women are notable, namely hot 
flashes and vaginal dryness (Goss, 1999). Therefore the search of aromatase inhibitors in 
steroid series must be done in series that is not belonging to androgens.   
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Because estrone 2 or estradiol 1 are formed as result of aromatization process it was possible 
to assume that these compounds will be reversible inhibitors of aromatase. Indeed, later it 
was found that even estradiol is anti-aromatase agent in human breast cancer cells 
(Pasqualini & Chetrite, 2006); the same was found for estrone sulfatase inhibition 
(Pasqualini & Chetrite, 2001). Simultaneously, reasoning from the same assumption, the 
synthesis of modified estrogens with substituents at ǿ-2, ǿ-4 or ǿ-6 was carried out 
(Numazava et al., 2005).     
These analogues are competitive inhibitors of aromatase. 2-Substituted steroids 47 a,b,c, 
have the best properties, they are significantly active in comparison with estrone 2, Ki values 
are 0.130±0.017, 0.224±0.024, 0.360±0.019 and 2.50±0.22 μM correspondingly. Steroids 48 and 
49 have similar activity - Ki values are 0.10±0.006 and 0.21±0.009 μM, however their 
synthesis is more complicated. Inhibitory activity of estradiol derivatives is significantly 
lower. From our point of view, its worth to pay attention to 2-fluoroestradiol 25, in spite of 
the value of Ki 9.04±0.5 μǺ being higher in comparison to other compounds and the fact, 
that its synthesis is more complicated. It is more important that this analogue does not 
possess carcinogenic properties in the experiments on rats (Liehr, 1983). In the series of 4-
substituted estrone derivatives – 4-fluoroanalogue 50 has the best properties (Кi = 1.28±0.07).  
All presented investigations had extensive character and it was impossible to take into 
account many details of biological properties. X-Rays analysis of complex of aromatase from 
human placenta with androst-4-en-3,17-dione 39 has been obtained (Ghosh et al., 2009), that 
opened the perspectives for the targeted search of aromatase inhibitors. Using the data 
obtained resulted in the docking of new reversible inhibitors in aromatase structure that 
allowed to explain their activity (Yadav et al., 2011).      
Aromatase inhibitors are widely used for the treatment of estrogen-dependent oncological 
diseases; however they have a number of side-effects. Thus, the decreasing of estrogen 
content in the body automatically results in the increasing of cholesterol level in blood, and 
hence to the increased risk of cardiovascular diseases. This is the main reason for the 
creation of inhibitors on the basis of steroids in comparison with non-steroid ones. For 
example, exemestane has minimal negative effects on bone and lipid metabolism in animal 
and clinical studies (Carpenter & Miller, 2005). There is an opinion that exemestane may 
improve lipid profile (Bundred, 2005).   
Molecular bases of interactions of various groups of ligands with aromatase have been 
considered relatively not long ago, that may lead to the creation of inhibitors with improved 
properties (Hong et. al., 2008). 
Aromatase inhibitors are important, but not sufficient for blocking of growth of hormone-
sensitive tumors. Point is that there is at least one more way for estrogens’ formation in 
tumors.  
It is known that estrone sulphate concentration in blood plasma of postmenopausal women 
is in 5-10 times higher in comparison with free hormone concentration. Assumption was 
made that estrogen sulphates may play a role of “source” of free estrogens in various 
organs, because its «half-life time» is longer than life-time of free estrogens (Reed & Potter, 
1999). Estrogen sulphates may migrate into hormone-depended tumor and then converted 
to free hormones under estrone sulfatase action. It was found that estrone sulfatase activity 
in tumors is in 130-200 times higher in comparison with aromatase activity (Chetrite et al., 
2000). This was the basis for initiation of investigations for the search for irreversible estrone 
sulfatase inhibitors.    
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Estrone sulfatase from human placenta is suitable model object for searching for 
corresponding inhibitors. It is the transmembrane protein that consists of 583 amino acid 
residues (mainly it is hydrophobic amino acids).  
On the basis of data about primary structure of this enzyme and taking into account its 
homology with human arylsulfatase A and human arylsulfatase B (X-Ray data of 
arylsulfatase were known), the structure of catalytic centre of estrone sulfatase was 
proposed (Howard et al., 2002). X-Ray data of estrone sulfatase has been obtained a little bit 
later and it was shown that its tertiary structure is formed by two domains – globular polar 
domain, containing the active center and transmembrane domain, formed by two 
antiparallel ǂ-helixes. Polar domain consists of two sub-domains, one of them has the active 
centre of enzyme. Transmembrane domain opens the entrance into the active center of 
enzyme, which is situated deep under the “mashrooms hat”, close to the membrane surface. 
Near the active center entrance a big amount of hydrophobic amino acids is concentrated, 
which are a part of TD (Phe178, 182, 187, 230, 233 and 237), and the polar domain (Phe104 
and 557, Leu554). Side chains of these amino acids form a tunnel, which leads to the active 
center (Hernandes-Guzman et al., 2003). Catalytic area of active center of estrone sulfatase 
is highly homologous to active centers of arylsulfatase A and В. Nine from ten catalytically 
important amino acids Asp35, Asp36, FG75, Arg79, Lys134, His136, His290, Asp342 and 
Lys368 are in analogous positions to all three sulfatases. It is in quite correlation with the 
experimental data about the importance of hydrophobic interactions during the binding of 
enzyme with inhibitors of steroid series (Ahmed S., 2001).  
Conceptions concerning estrogen sulfates hydrolysis mechanisms and ferment deactivation 
are presented in series of articles (Reed et al., 2005), where an important role is assigned to 
an unusual amino acid - formylglycine in 75 position. 
Investigation of kinetic parameters of hydrolysis of estrone sulphate and 
dehydroepiandrosterone sulphate have shown that values of Vmax for these compounds are 
correspondingly 9.95 and 1.89 μM/min, values of Km are 72.75 and 9.59 μM (Hernandez-
Guzman et al., 2001). These values could be used as standard for the evaluation of substrate 
specificity of estrone sulfatase of various natures.  
In several investigations it was established that for the effective inhibition of estrone 
sulfatase molecules must have sulphamate group at position 3. Firstly the necessity of this 
group was demonstrated on the example of steroid 51a, widely known as EMATE (Purohit 
et al., 1995). However this compound did not reach the clinical application as anti-tumor 
agent because its estrogenic activity under per os introduction is in 5 times higher in 
comparison with estrone (Elger et al., 1995).    
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The investigations of Professor M. Reed’ group are examples of the successful creation of 
estrone sulfatase inhibitors with lowered hormonal activity (Purohit et al., 1998), authors 
have synthesized compounds 51a-j. The selection of modifications in EMATE structure was 
done on the basis of experimental facts about significant fall of uterotropic activity of 
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estrone derivatives when substituents like alkyl-, allyl- or nitro- groups were introduced at 
positions 2 and (or) 4 (Purohit et al., 1999). Some results on human placenta microsomes 
enzyme are presented in the Table 1. 
 
Steroid R1 R2 IC50, μM Steroid R1 R2 IC50, μM 
a ǻ ǻ 0.004 f H CH3(CH2)2 > 100 
b OMe H 0.03 g CH3(CH2)2 CH3(CH2)2 > 100 
c NO2 H 0.07 h Allyl H 2.5 
d H NO2 0.0008 i H Allyl 9 
e CH3(CH2)2 H 29 j Allyl Allyl > 100 
Table 1.  
Irreversible E-ST inactivation has been observed in all cases. Most active inhibitor from this 
series is – 4-nitro derivative 51d – in 5 times stronger than ЕǺАТЕ in vitro and had 
comparable activity with ЕǺАТЕ activity in vivo. The investigation of uterotropic activity 
has shown that this steroid increases uterus weight of ovariectomized rats, although to 
lesser degree than ЕǺАТЕ (158% in comparison with control, and 414% - ЕǺАТЕ). 
Monoallylic analogues are weaker inhibitors estrone sulfatase, but they are more active in 
comparison with propyl- ones. The presence of large substituents at ǿ-2 and/or ǿ-4 leads to 
decreasing of inhibitory activity, which may be caused by shielding of oxygen atom at ǿ-3. 
Estrone formiate 52 (Schreiner & Billich, 2004) and boronic acids 53 (Ahmed, V., 2006) have 
shown irreversible inhibitory activity, however these investigations had no further progress.     
R
H
H H
N
S
O
O
O
H
H H
NH
2
O
2
SO
H
H H
COOCH
2
CH
3
NH
2
O
2
SO
 
                              54                                         55                                    56 
O
H
H
NH
2
O
2
SO
O
H
H H
NH
2
O
2
SO
N
H
O
H
H H
NH
2
O
2
SO
O O
 
                                     57                                         58                                        59 
H
H H
R'O
N
O
O
H
H H
R'O
N
O
O N
R' = Bn, H, SO2NH2
 
                                           60                                                                    61 
www.intechopen.com
Approaches for Searching 
of Modified Steroid Estrogen Analogues with Improved Biological Properties 
 
185 
Compounds of type 54 were chosen as an example and authors used another analogue 
(oxatiazine ring, condensed with A ring) instead of sulphamate group at C-3 (Peters et al., 
2003). In the experiments in vitro in an intact MCF-7 human breast cancer cells model 
steroids have shown high inhibitory activity. In vivo, agent 54 showed moderate antitumor 
activity against MCF-7 breast cancer xenografts in BALB/c athimic nude mice. 3,4-
Oxathiazine analogues showed weak inhibitory activity.  
Compounds 55-57 effectively inhibit estrone sulfatase (Tanabe et al, 1999). It indicated 
specifically on the possibility for the creation of inhibitors in the series of D-homo analogues 
of estrogens that was confirmed using sulphamates 58 and 59 (Reed & Potter, 1999). 
The development of this direction led to the creation of strong inhibitors 60 and 61 with 
values of IC50 - 1 nM (Fischer et al., 2003). 
One more group of perspective inhibitors of estrone sulfatase was found – sulphamates of 
estrogens with methoxy- group at ǿ-2 (Raobaikady et al., 2003). At the time of these 
investigations it was known that 2-methoxyestradiol 62 induces apoptosis in many various 
lines of tumor’ cells, including prostate cancer cells, exhibits antiproliferative activity and 
blocks angiogenesis processes, which became a basis for the selection of model compounds.  
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The fact that bis-sulphamates of 2-methoxyestradiol 63 and 2-ethylestradiol 66 inhibit the 
growth of breast cancer cells, which are resistant to the action of many medications, has a 
crucial importance (Suzuki et al., 2003).  
We have considered the ways for the search for modified estrogens for the inhibition of 
steroids metabolism enzymes which have been done in series of derivatives with natural 
rings junction. Obvious perspective direction is the investigation of analogues with 
unnatural rings junction since peculiarities of their structure have the number of important 
characteristics, comparable with ones in series of natural estrogens and comparable 
biological properties of both series.  
It is known that high effectiveness of binding of estradiol 1 with ER is a result of high 
hydrophobicity of steroid molecule and possibility to form hydrogen bonds of phenolic 
hydroxyl group at ǿ-3 with Glu353, Arg394 and water molecule. Hydroxyl group at ǿ-17 
forms hydrogen bond with His524 (Brzozowski et al, 1997). Modified 8-analogues of 
steroid estrogens have relative high affinity to ER, and model explaining the binding with 
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ER has been proposed (Shavva et al., 2002 and citation herein). Metabolism of steroids 
with unnatural rings junction may be quite different from metabolism of natural steroids, 
which will allow to find the alternative solutions of many medicinal-biological tasks.  
The perspectives for the creation of new inhibitors of steroid metabolism have been 
demonstrated using 6-oxa-D-homo-8-analogues of estrogens 67 as an example (Gluzdikov 
et al., 2007). Authors accomplished the docking of different compounds of this series into 
ligand-binding domain of ER. And after the analysis the assumption was made that this 
compound must have weak binding affinity to ER or must have none in total. Sulphamate 
67а has been synthesized and the analogue showed a quite good inhibitory activity to 
estrone sulfatase. Steroid 67b - potential product of hydrolysis has no uterotropic activity. It 
became the basis for the improvement of synthesis scheme of 7-methyl-D-homo-8-
analogues of steroid estrogens (Morozkina et al., 2009) and investigation of peculiarities of 
their spatial structure (Shavva et al., 2008). Steroids of such structure may be used for the 
solution of other tasks (for example, as vectors for the transport of other classes of 
compounds into estrogen target-tissues).  
Finally, 17-hydroxysteroid dehydrogenase type 1 plays the important role in the induction 
and development breast cancer (Vihko et al, 2002). In ER+ breast cancer cells under the 
action of this enzyme the dominate direction of the reaction is the transformation of estrone 
into more dangerous estradiol. In ER-positive breast cancer cells the reaction tends to 
proceed in the reverse direction. Another reason of tumor growth is inactivation of 
dehydroepiandrosterone 68, which blocks tumor growth (Aka et al., 2010). 
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Substrate specificity of available enzyme from human placenta was investigated and it was 
found that steroids of unnatural series are also substrates for this enzyme (Egorova et al., 
1973). High substrate specificity was observed only in the case of trans-junction of C and D 
rings. Values of Vmax of 8ǂ-series steroids may be more than ones for compounds of natural 
series. For example, Vmax value of 8-estradiol 69а is 219% of Vmax value of estradiol. D-
homo-8-estradiol 70а has value of Km in 5 times less than estradiol value, whereas values 
of Vmax are approximately equal. Methylation of phenolic group (analogue 69b) leads to the 
decreasing of Km value in one order, steroid 70b has value of Km in 2.5 times less than 
compound 70а. It takes attention big values of Vmax of steroids 71 and 72, correspondingly 
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635 and133% in comparison with estradiol (Langer et al., 1959). Values of Km and Vmax of 2-
hydroxyestradiol 72 are comparable with these values for estradiol 1 (Chernyaeva et al., 
1972), and such modification may be important during the search of inhibitors of 17-
hydroxysteroid dehydrogenase. Hence, the presence of free hydroxyl group at ǿ-3 is not 
necessary for significant substrate specificity of such steroids. Modified androgens are also 
substrates for this enzyme, although they are notably less specific (Chernyaeva et al., 1972). 
The abovementioned fact gives a persuasion that the search of inhibitors of investigated 
enzyme is most perspective in the series of steroids with unnatural rings junction. As far as 
we know such investigations have not yet been done.  
It is quite interesting, that 2F- and 4F-estradiols (correspondingly 25 and 50) are not 
substrates for 17-hydroxysteroid dehydrogenase (Langer et al., 1959), which may be 
important during the search of compounds with different spectrum of biological 
properties.     
Primary structure of this enzyme was determinated after the analysis of corresponding 
ȟDNA (Peltoketo et al., 1988), lately X-rays analysis was obtained (Ghosh et al., 1995). The 
comparison of spatial structures of 17-hydroxysteroid dehydrogenase and investigated 
earlier 3,20-hydroxysteroid dehydrogenase (Ghosh et al., 1994) led to the conclusion 
about participation of His in the binding of hydroxyl group at C-3 of steroid and structure of 
transition state with the participation of triad Tyr-Ser-Lys. Authors justly mention the 
importance of the data obtained for modeling of interactions of 17-hydroxysteroid 
dehydrogenase with various ligands for the creation of effective inhibitors of the enzyme. 
Interesting developing of these investigations was the modeling of spatial structures of the 
enzymes of humans and rats, which are significantly different in primary structure and 
substrate specificity. Rat enzyme structure was modeled by the replacement of 
corresponding amino acids in the structure of human enzyme crystal (Ghosh et al., 1995) 
and following minimization of energy was done (Putanen et al., 1997). Results of 
calculations of rat enzyme are in good correlation with obtained experimental data. 
Clarification of mechanism of action of both enzymes was done using chimeric enzyme and 
site-directed substitution.       
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X-rays data of the complexes of 17-hydroxysteroid dehydrogenase with estradiol 1 
(Azzi et al., 1996), 5-dihydrotestosterone 73 and 20-hydroxy-analogue of progesterone 
74 (Lin et al., 1999) have been obtained lately. Nevertheless the preliminary evaluation of 
characteristics for the searching the specific potential inhibitors is quite a difficult task 
because in human body types 1, 7 and 12 catalyze the transformation of estrone into 
estradiol (Blanchard & Luu-The, 2007). Substrate specificities of 17-hydroxysteroid 
dehydrogenases type 1 and 2 are similar, but in the case of second enzyme the 
transformation reaction estradiol – estrone is mainly directed to estrone formation 
(Miettinen et al., 1996), therefore the inhibition of this enzyme during the treatment of 
hormone-sensitive breast cancer is quite undesirable. The search of specific inhibitors of 
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17-hydroxysteroid dehydrogenases type 1 is complicated task, the attempts to solve this 
task by replacement oxygen-containing groups at position 17 and introduction of 
fluorine atoms into the same position of steroid skeleton were unsuccessful (Deluca et 
al., 2006).   
Steroid 75 with big value of IC50 (530±7 nM) to this enzyme was synthesized, and this 
analogue has no hormonal activity (Fisher et al., 2005). Authors also obtained X-Ray data 
for the complex of compound 76 with 17-hydroxysteroid dehydrogenase type 1 that has 
importance for the solution of this task.  
Investigation of inhibitory activity of estrogen analogues with large substituents at ǿ-16 in 
-position led to find steroids 77 and 78 with selective action (Lawrence et al., 2005). 
Analogue 77 has value of IC50 0.29 μM to 17-hydroxysteroid dehydrogenase type 1 
(Purohit et al., 2006).   
Parallel investigations of properties of modified estrogens with substituents in -position 
at ǿ-16 led to obtain the compounds of type 79 (Laplante et al., 2008), this steroid has 
value of IC50 44±7 nM for the transformation estrone 2 into estradiol 1 in T-47D intact 
cells. Unfortunately, analogue 79 possesses estrogenic activity, although this activity is 
decreased. 
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Obviously, clinical application of specific inhibitors of all three discussed enzymes is an 
intermediate step in the search for medications for the treatment of estrogen-sensitive 
oncological diseases. The most perspective direction is the search for compounds with 
simultaneous/synchronous inhibition activity to aromatase, estrone sulfatase and 17ǃ-
hydroxysteroid dehydrogenase. The basis for this approach is the possibility for 
overexpression of aromatase in tumors, which was shown in experiments on MCF-7 cell 
lines (Santen et al., 1999). Aromatase may stimulate the growth of tumors through both 
autocrine and paracrine pathways (Chen et al., 1999). Moreover, long-term estrogen 
deprivation increases sensitivity to estradiol and enhances aromatase activity in MCF-7 cells 
(Yue et al., 1999).  
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Both substrate specificity of enzymes and potential ways of inhibition metabolism must be 
taken into account during the search for steroid hormone synthesis inhibitors. The fine 
example of inhibitors which are able to inhibit the activity of aromatase and estrone 
sulfatase at the same time was demonstrated by Japanese authors (Numazava et al., 2005; 
2006). In earlier investigation it was demonstrated that steroids 25, 47a,b,c and 48-50 are 
good inhibitors of aromatase. Sulphamates 80a,b,c and 81-83 having higher activity in 
comparison with EMATE have been synthesized. Authors justly think that these results may 
be useful for the development a new class of drugs having a dual function for the treatment 
of breast cancer. Additional benefits of the modifications at positions 2-, 4-, and 6 of steroid 
skeleton are perspective in respect of the fact that they may decrease the potential 
carcinogenicity of hydrolysis products (if they have) since the decreased possibility of 
formation of danger о-quinones of type 29 (Liehr et al., 1995, 1996; Bolton et al., 1998; 
Bolton & Thatcher, 2008; Zhang, F. et al., 1999; Liu, X. et al, 2002; Zhang, Q. et al., 2008) or 
6-hydroxyestrogens (Itoh et al., 1998).   
Search for non-steroidal inhibitors of aromatase and sulfatase is of interest as well. Such 
properties belong to heterocyclic sulphamates (Reed & Potter, 2006), however the 
perspectives for its using in clinic is not clear at the moment.    
The attempts of synthesis of steroids with multifunctional action, in particular, inhibitors of 
ERs and 17-hydroxysteroid dehydrogenase type 1 were done (Tremblay & Poirier, 1996). 
Steroid 84 was selected as model compound by authors on the basis of previous data. Earlier 
it was established that in the series of 16-(bromoalkyl)estradiols for the realization of 
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inhibitory action the presence of side chain (3-4 carbon atoms) at position 16 is optimal. 
Such substituents contribute to the appearance of antagonist activity to ER. It is desirable 
to have the tertiary amide group with substituents on the amide nitrogen. Authors assumed 
that primary bromide will inactivate 17-hydroxysteroid dehydrogenase. Thus, steroid was 
expected to be inhibitor of 17-hydroxysteroid dehydrogenase and agonist-antagonist to 
nuclear estrogen receptor. These suppositions have been confirmed: model steroid caused 
25% stimulation of cellular growth at concentration 0.1 μM, at the same concentration 
steroid inhibited by 45% the 0.1 nM estradiol-stimulated growth of ZR-75-1 cells. It means, 
that compound 84 is partial agonist of ER and inhibitor of 17-hydroxysteroid 
dehydrogenase with moderate activity.  
Sulphamates 85 and 86 are inhibitors of estrone sulfatase and 17-hydroxysteroid 
dehydrogenase (Potter & Reed, 2002; Messinger et al., 2006).   
The selection of ways for the treatment of oncological diseases mainly depends from 
individual peculiarities of patients, as result the methods of definition of aromatase, estrone 
sulphatase, 17-hydroxysteroid dehydrogenase or mRNA (which realizes their synthesis), 
content have a crucial importance (Irahara et al., 2006).  
5. Modified estrogens with antioxidant action as potential neuroprotective 
agents 
Estradiol and its analogues have been known to have pro- and antioxidant features. These 
properties of estrogens are still subject of debate and depend on many factors, including 
animals or tissues, administration routes, concentrations, peroxidative model and so on. 
Antioxidant action of estrogens has been widely studied in vivo and in vitro. Aside from its 
effects on LDL-oxidation (Badeau et al., 2005), it has reported that estrogens decreased lipid 
peroxidation in brain homogenates and neuronal cultures (Thibodeau et al., 2002), reduced 
the superoxide anion production in different cells (Florian et al., 2004),  
In vivo studies allow usage of different experimental models of neurological disease 
(Azcoitia et al., 2002). Among the steroid family, only estrogens have the capability to 
prevent neuronal cell death caused by oxidative stress. Estradiol has been reported to 
reduce mortality and cerebral damage in the models of brain ischemia including middle 
cerebral artery occlusion and common artery occlusion (Perez et al., 2005). The 
neuroprotective effect of estrogens have also been shown in animal model of Parkinson’s 
disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and in experimental 
models with various toxicities including serum deprivation, amyloid  peptide, glutamate-
induced excitotoxicity, kainic acid and so on (see reviews Green  Simpkins, 2000; 
Amantea et al., 2005). Estrogens may protect against injury via receptor-dependent and 
receptor-independent mechanisms and it has been suggested that antioxidant capacity is an 
important component of the complex neuroprotective effect (Green  Simpkins, 2000; 
Prokai  Simpkins, 2007).  
Antioxidant activity of estrogens as well as other known antioxidants in vivo is determined 
by a lot of factors: concentrations, distribution, localization, fate of antioxidant-derived 
radical, interaction with other antioxidants, metabolism (Niki  Noguchi, 2000). Natural 
fluctuation of ovarian hormones during estrous cycle may influence the effect of exogenous 
hormones; therefore ovariectomized animals are often used. Another problem with this 
approach is that estrogens can be transformed in tissues into metabolites, for example to 
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catecholestrogens, that have another antioxidant property and can produce prooxidants 
(Picazo et al., 2003). Most animal studied have utilized rodents (especially rats), that have a 
very high rate of estrogen degradation. Further, in case of brain the synthetic estrogens that 
are candidates for neuroprotective antioxidants in vivo should be able to cross the blood-
brain barrier after their systemic administration. In vivo estrogens probably do not exert 
their own antioxidant action but interact synergistically with other antioxidants or 
reductants (Hwang et al., 2000). They can also affect the redox state of the cell through 
alteration of glutathione concentration and enhance the production of high energy 
compounds, stimulate antioxidant enzymes, such as SOD, catalase or glutathione 
transferase (Perez et al., 2005; Akcay et al., 2006; Siow et al., 2007; Kumtepe et al., 2009). 
Using in vivo methodology we can not understand molecular mechanisms of certain 
hormone antioxidant action, but it allows studying the manifestation of complex action of 
hormone treatment.  
More than 12 different types of neuronal cells against the 14 different toxicities were used to 
investigate neuroprotective effect of estrogens, their analogues and derivatives (Green  
Simpkins, 2000; Wise et al., 2001). The concentrations of estrogens that have produced 
protective action in these models vary from physiological (0.1 nM) to pharmacological (50 
M) and it is suggested that different neuronal types may have different sensitivities to 
estrogen-mediated protection. For example physiological concentrations of 17-estradiol 
were neuroprotective in cultures that contain multiple cell types and maintain intact cellular 
architecture (Dhandapani  Brann, 2007). Several studies provide a positive correlation 
between in vitro neuroprotective potency and antioxidant activity of estrogens: they 
inhibited lipid peroxidation induced by glutamate, iodoacetic acid, amyloid  peptide 
(Perez et al., 2005; Prokai-Tatrai et al., 2008), reduced iron-induced lipid peroxidation 
(Vedder, et al., 1999), prevented intracellular peroxides accumulation induced by different 
toxicities (Behl et al., 1997). The neuroprotective antioxidant activity dependents on the 
presence of OH-group in the C-3 position on the A ring of the molecule. The formation of 
ether derivatives at C-2 position reduces effect because it abolishes the ability to donate a 
hydrogen atom (Prokai et al., 2001; Perez et al., 2005).  
However, adjoin electron-donating methoxy groups to the phenolic ring may enhance 
antioxidant potency by weakening the phenolic O-H bond and provide stability of the 
formed phenoxyl radical (Prokai  Simpkins, 2007). Nevertheless generally higher 
concentrations of the hormones were required for antioxidant action than were needed for 
neuroprotection. This observation indicates that antioxidant effect is not a significant 
mechanism involved in the neuroprotective activity of estrogens in vivo (Wise et al., 2001; 
Manthey  Behl, 2006).  
The simplest level of in vitro study of radical scavenging activity is investigation using cell-
free models. Oxidation is induced by different systems of free radical generation and 
different types of prooxidants in order to gain a more precise view of the mechanism of 
inhibition. This methodology allows to investigate basic chemical properties (antioxidant or 
prooxidant) of natural estrogen molecules or synthetic analogues and compare compounds 
in each other.  
There are multiple reactive oxygen and nitrogen species (ROS and NOS) and free radicals: 
superoxide radical (O2-), hydroxyl radical (HO), hydrogen peroxide (H2O2), nitric oxide 
(NO), peroxynitrite (ONOO-), hypochlorous acid (HOCl), peroxyl radical (ROO), 
lipoperoxy radical (LOO). The reactivity toward various ROS or NOS can be measured by 
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the inhibition methodology in which free radical species are generated in a special model 
system and the antioxidant effect is measured by inhibition of the reference reaction 
(Sanchez-Moreno C., 2002). For the superoxide anion radical generation a few model 
systems can be used: for example, hypoxanthine-xanthine oxidase system, autooxidation of 
riboflavine or non-enzymatic reaction of phenazine methosulphat in the presence of NADH 
and O2. Then O2- reduces nitro-blu tetrazolium into formazan at 250C and pH=7.4.  
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It is important to note that antioxidant action of estrogens is not necessarily depends on 
their receptors (Xia et al., 2002; Perez et al., 2005). This allows to search for modified 
analogues with lowered or depleted hormonal activity. It appeared that, for example, ent-
estradiol 87 has antioxidant properties (Simpkins, 2004). The introduction of conjugated 
with aromatic ring double bond into steroid molecule leads to the increased antioxidant 
activity (steroids 88 and 89) (Römer, W.; Oettel, M.; Droescher, P.; Schwarz, S., 1997) and 
compound 90 (Römer et al., 1997) in comparison with estrogen without double bonds. 
Steroids of type 88 have significant hypothalamic action (Berliner, 1996), that allowed them 
to be recommended for the treatment of autoimmune diseases. 
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As we have noted earlier, presence of hydroxyl groups at C-3 and at C17 is important for 
effective binding of estrogens with estrogen receptors. As the first group is necessary for 
antioxidant activity of estrogen, synthesis of analogue with substituents at C-17 and/or 
aromatic ring, which would prevent receptor binding, would be an easy solution of the 
problem.  
Thus, 17-methylensteroid 91 in the experiments on 23-day-old Sprague-Dowley rats exhibits 
only 1/70 of the uterotropic activity of estradiol. Moreover, this compound blocks the action 
of 7,12-dimethylbenzanthracene (Jungblat et al., 1990). Although in this work the 
investigation of antioxidant activity of compounds is not mentioned, it must be present in 
analogy with 17-difluoromethylene derivative 92 (Bolhman & Rubanii, 1996). In spite of 
that steroid has positive action on cardiovascular system; such compounds may have only 
restricted application because this steroid possesses contraceptive activity. We have to note 
that biological properties of 8-analogue 93 are close to properties of steroid 92 (Bolhman & 
Rubanii, 1996). Analogues of type 93 decrease lipoprotein level.  
The synthesis of steroid ethers in position 17 also could have lead to compounds having 
antioxidant activity coupled with lowered uterotropic action, as it was shown with 
compounds such as 96 (Prokai et al., 2001; Prokai & Simpkins, 2007). Thus, the presence of 
large substituents in ring D does not result in lowered antioxidant properties, hence 
synthesis of new compounds which would possess double bond at position 8(9) and large 
substituents at D-ring can be considered as the next step in the creation of new drugs. It is 
desirable that these substituents had free phenol hydroxyl group, which would 
automatically increase its antioxidant properties. In fact, steroids 94 and 95 do have 
desirable properties (Römer et al, 1997).  
The introduction of large substituent at position 2 must lead to decrease of estrogenic 
properties of modifies analogue at the presence of antioxidant activity, that was 
demonstrated with compounds 97 (Miller et al., 1996) and 98 (Simpkins et al., 2004) as 
examples.  
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                                    99                                        100                                    101 
The high antioxidant activity of steroid 99 has been shown on different models (Klinger et 
al., 2003). Unfortunately this compound strongly inhibits monooxidaze activity of 
cytochrome Ǿ450 that is undesirable.       
Hydroxyl group at ǿ-17 in ǂ-region of molecule does not prevent the appearance of 
antioxidant properties (compounds 100 and 101), which opens additional possibilities for 
the obtaining compounds with the selective action (W. Römer, M. Oettel, P. Droescher, S. 
Schwarz, 1997).  
Antioxidant properties of 6-oxa steroid estrogen analogues have undergone little 
investigation. Oxygen atom does obviously possess a big influence on electron density 
distribution in A ring, which can have an impact on antioxidant properties of such 
compounds. Difference in antioxidant action mechanisms between such compounds and 
those discussed earlier can be assumed (Prokai-Tatrai et al., 2008).   
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We carried out the search for modified steroid estrogen analogues in the series of steroids 
with unnatural rings junction having antioxidant properties and lowered/depressed 
uterotropic activity. Such properties belong to compounds 102 (Pison et al., 2009) and 103. 
Some results of investigations of antioxidant properties of steroid 102 are presented in the 
Table 2.  
O
OAc
H
H
CH
3
O
H
O
H
H
OH
 
                                                               102                              103 
 
Experimental 
conditions 
Schiff bases, 
conventional 
units / mg of 
phospholipids
Conjugated 
diene, 
nmol/mg of 
phospholipids
Triene 
conjugates, 
conventional 
units / mg of 
phospholipids
Klein 
coefficient
Malonic 
dialdehyde, 
nmol/mg of 
phospholipids 
Control 12910 12.20.7 0.2090.022 0.700.01 1.650.14 
Steroid 102 966 
Ǿ0.05 
9.51.0 
Ǿ0.05 
0.1520.022 
Ǿ  0.05 
0.710.05 
Ǿ  0.05 
1.800.18 
Ǿ  0.05 
P – Student’ coefficient.  
Table 2. Results of investigation of action of steroid 102 on lipid peroxidation in brain of rats 
Steroid was given per os in olive oil in dose 5 mg per 100 g of weight of rats, for the day 
before the slaughter. Solutions of the steroids contain 5 mg in 0.3 ml. Control group of 
animals were treated by olive oil in equal volume. 
Solely further investigations of such compounds may show the perspectives of this class of 
steroids. Depressed hormonal activity of investigated steroids may be a negative factor, 
inasmuch as during their using the capacity for the induction of the formation of enzymes 
with antioxidant properties will be decreased.  
The presence of antioxidant activity leads to expect neuroprotective action of such modified 
estrogens, in spite of the fact that exact mechanisms of these properties have not yet been 
established. A huge amount of patents in this area is a proof of it. We shall cite some of those 
works (Simpkins et al, 1994; Covey, 2002; Wuelfert et al, 2002; Peri et al., 2005; Pei, 2005). 
Unfortunately clinical trials did not confirm neuroprotective action. Most probably it is 
connected with multifunctional activity of estrogens, and as a result their positive properties 
are “compensated” by negative action, but how and which ones are unknown. Further 
progress in this area must be connected with success in detailed investigation of mechanism 
of neuroprotective properties and synthesis of analogues with restricted action.  
6. Osteoptotective action of estrogen receptors ligands 
Several animal modes are used to test new compounds with osteoprotective properties. 
Ovariectomized mice are the ones most commonly used. Although aging in rats does not 
trigger osteoporosis development, ovariectomy-driven low estrogen concentration leads to 
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changes in bone tissue, which mimic those occurring in aged women. At first phase of fast 
bone tissue loss triggered by accelerated bone remodeling occurs. Later on this process 
slows down. Trabecular tissue becomes depleted more so then cortical tissue. It should be 
noted that bone breaking is rarely observed in ovariectomized rats, thus is probably better to 
call this process osteopeny.  
There are known several models for testing steroids on animals. When investigating the action 
of compounds in mature rats at the age of 3 months intensive growth of bones in longitudinal 
direction should be taken into account. 75 Days old (Turner et al., 1994) rats are more suitable 
for the investigation; rats model (6-12 months), which has very few skeletal changes, are much 
harder to work with. To test bone state several parameters are used, such as «bone mineral 
density» (g/cm3) and «bone mineral content» (g/sm. length, g/sm2). Last parameter has linear 
correlation with bone mass (r=0.999) (Sato et al., 1995) and calcium contain in ash after bone 
burning (r=0.90) (Gaumet M., 1996). By measuring dry weight of the bone (after drying at high 
temperature until the constant mass is obtained), ash weight after burning (Bauss et al., 1996), 
and also by investigating the ratio of this two parameters (Broulik & Schreiber, 1994) changes 
in mineral bone content can be measured. Results of dual-energy X-rays absorptiometry BMD 
correlate with fracture incidence and useful in evaluation progression of osteoporosis (Sharp 
et al., 2000). Yet, the final conclusion about steroid activity can only be given after the 
investigation of their influence on mechanical durability of the bone (Turner et al., 1994; Sato 
et al., 1999). All the works in this part were investigating naturally occurring steroids.  
As we have already noted the significant structural similarity between natural steroids and 
their 8-analogues, the osteoprotective and uterotropic action of these compounds were 
investigated. In experiments with ovariectomized Wistar rats parallel change in those effects 
was observed. It was suggested that osteoprotective activity is dependent on nuclear -
receptor of estrogens (Morozkina et al., 2007). Hence analogues were chosen as model 
compounds, despite the fact that presence of methoxyl group at ǿ-3 was expected to trigger 
the lowering of activity. However in this case carcinogenicity was also expected to be 
lowered. In the experiments with Sprague-Dowley rats compounds 104 and 105 were shown 
to possess the same osteoprotective activity as ethynylestradiol, although they were 
administered in higher doses (Morozkina et al., 2008). The presence of substituents in 
positions 2 and 4 cancels the osteoprotective effect. 
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We assumed that steroid 106 may have osteoprotective action on the analogy with tibolone. 
It was confirmed experimentally; however compound 106 has embriotoxic action in 
experiments of contraceptive properties investigations which possibly decreases 
significantly the perspectives of such analogues. 
OH
O
NMe
2 O
NMe
2
Cl
CO
2
H
SOH
O
O
N
OMe
 
    Droloxifene               Toremifene                    GW5638                     LY353381 (arzoxifene) 
           107                              108                                109                                         110 
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        CP335156 (Lasoxifen)                     HMR3339                             Bazedoxifene 
                        111                                           112                                           113 
As ER modulators are capable of displaying antagonistic properties in uterus and mammary 
gland while retaining agonistic features in bone, perspectives of using such compounds as 
osteoprotectors was investigated. Raloxifene has very effective osteoprotective properties. 
Clinical studies have shown that, aside from osteoprotective effects, the risk of breast cancer 
was also lowered (Fontana & Delmas, 2001). Interestingly that osteoprotective effect of 
raloxifene is not always mediated by ERs (Miki et al., 2009), and as the result the properties 
of its analogues may be quite interesting. However it was established that raloxifene in this 
case has some negative properties, peculiar to typical estrogens (high risk of hot flashes, leg 
crumps and venous thrombosis (Deal & Draper, 2006). In view of the aforesaid it is worth to 
remember about earlier synthesized compound LY357489 (Grese et al., 1998), whose 
osteoprotective action is significantly higher in comparison with raloxifene. This compound 
is the conformationally restricted raloxifene’ analogue; its selective action was explained by 
specificity of interaction with ERs. Probably, it is necessary to investigate the mechanism of 
this compound’ action.       
Lately a huge number of SERMs with osteoprotective action have been synthesized, for 
example droloxifene 107 (Ke et al., 1995; Chen, H.K. et al., 1995), LY 353381 (arzoxifene 110) 
(Sato et al., 1998; Ma et al., 2002), lasofoxifen (CP-336,156) 111 (Ke et al., 1998; 2000, 2004), 
GW5638 109 (Wilsson et al, 1997) and many other compounds with interesting biological 
properties. For example, lasoxifen (CP-336,156) showed osteoprotective and cholesterol-
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lowering properties, decreased body weight in the experiments on ovariectomized rats. This 
compound had osteoprotective action in adult male orchideectomized rats, and has not 
influence on prostate (Ke et al., 2000). 
Droloxifene showed interesting biological properties in the experiments with animals, such 
as osteoprotective action in aged female rats (Chen, H.K. et al., 1995). However it was 
shown to be less effective then tamoxifen in breast cancer treatment clinical studies, so its 
investigation was stopped (Vogelvang et al., 2006).     
Lasoxifen showed osteoprotective and cholesterol-lowering action while lowering body 
weight of ovariectomized rats. This compound also displayed osteoprotective properties in 
adult male orchideectomized rats while having no effect on prostate (Ke et al., 2000). As far 
as we are aware, effectiveness of lasofoxifen have not undergone clinical studies.  
Idoxifene was used in clinical trials on patients, whose tumors were resistant to tamoxifen, 
however third-generation aromatase inhibitors took its place, clinical data about its 
osteoprotective properties are conflicting (Vogelvang et al., 2006).  
Preliminary studies of breast cancer treatment by HMR3339 and its osteoprotective 
properties provided results that may be considered positive (Vogelvang et al., 2006).    
Bazedoxifen possesses promising properties. As a result of 5 years long clinical study on 
4216 patients in postmenstrual period good osteoprotective properties were found 
(Silverman et al., 2010).  
We have already mentioned the possibility of agents’ synthesis in 8-analogues of steroid 
estrogens series with osteoprotective properties. Preliminary results are presented in Table 
3. 17-ethynylestradiol was used as standard.  
 
Group of experimental rats 
(number of animals in the 
group) 
Change of 
body weight,
Uterine weight, 
mg/100 g of 
body weight 
Ash femur 
weight/wet 
femur weight 
Bone mineral 
density, 
g/cm2 
Sham-operated (10) 29±3* 154 ± 4* 0.432±0.007* 0.258±0.005* 
Ovariectomized (15) 60±5 22.7 ± 0.5 0.398 ±0.005 0.231±0.003 
Ovariectomized, treated 
with EE (10)  
12±4* 140± 6** 0.433±0.005* 0.255±0.006* 
Ovariectomized, treated 
with steroid 69a (10) 
7 ± 4* 148± 6** 0.425±0.006* 0.258±0.007* 
Ovariectomized, treated 
with raloxifen (10) 
33±5* 46.5 ± 2.6* 0.430±0.007 0.245±0.006* 
Ovariectomized, reated 
with raloxifen and steroid 
69a (15)  
38±5* 31.2 ± 1.2* 0.425±0.005* 0.248±0.006* 
Signs * and ** mean statistically significant difference between studied group and group of 
ovariectomized animals, Ȟ<0.05 and Ȟ<0.01 (Students t-criterion).  
Table 3.  
According to the data, this compound possesses osteoprotective properties. Also, in contrast 
to action of 17-ethynylestradiol and steroid, combination of compound and raloxifene did 
not trigger hypertriglyceridonemy, yet cholesterol-lowering effect remained. There is no 
doubt that investigations regarding properties of 8-series steroids are of great importance. 
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The new area in synthesis of compounds with osteoprotective properties should be noted – 
the creation of hybrid molecules having steroid and peptide fragments, for example 
compounds (Wang et al., 2003). Such compounds have stronger action in the experiments 
on rats in comparison with sum of action of these compounds.   
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                                        114                                                                        115 
Peptidylsteroid 114 has very interesting properties (Yokogawa et al., 2006). This hybrid 
compound during intranasal administration has a potent antiosteoporotic effect without 
side effects in experiments on female ddY mice.  
In the treatment of estrogen-sensitive conditions aromatase inhibitors are to be used 
sometimes, which triggers estrogen concentration to drop, increasing osteoporosis and 
cardiovascular disease risk (Ponzone et al., 2008; Reid, 2009; Gennari et al., 2011). In each 
case the decision in using a drug depends on individual features of the patient. Usage 
combined drugs, which have calcitriol as a part of them, might prove useful to lower 
osteoporosis (Krishnan et al., 2010).      
7. Steroid estrogens and cardiovascular system 
Coronary heart diseases (CHD) is rare, and the incidence of CHD complications is much 
lower in premenopausal women then in man or postmenopausal women of similar age. 
After menopause the gender difference is lost and the incidence of CHD complications in 
women gradually approach that the men. In addition, menopause adversely affects several 
risk factors for CHD. It allows to assume the important role of estrogens in the protection of 
body from coronary heart diseases and expediency of their use as HRT medications.  
Protective effect of estrogens has been shown in various animal models. 
Rats have been used as a model system to study estrogenic effects on plasma lipid levels 
(Lundeen et al., 1997). On the whole this model has a lot of restrictions, first of all the main 
one is the predominant plasma cholesterol is HDL, not LDL, as it is in human. There are 
known: mouse models of atherosclerosis (Hodgin & Maeda, 2002) on rabbits (Haarbo & 
Christiansen, 1996) and primates (Adams et al., 1990). In all cases the main is the evaluation 
of influence of estrogens on the development of atherosclerotic plaque or lesion. In most 
cases it was shown the inhibitory activity of estrogens on atherosclerosis development.   
Firstly it was postulated that main antiatherosclerotic action of estrogen is caused by the 
ability to decrease cholesterol level in serum; however in a number of investigations it was 
shown that this mechanism is not obligatory (Shavva et al., 1987; Holm et al., 1997). 
At the present time it is postulated that atheroprotective effects of estrogen may be mediated 
by their nuclear receptors. ERǂ was found in endothelial cells (Venkov et al., 1996), in 
smooth-muscle cells (Karas et al., 1994) and in myocardial cells. A number of authors 
maintain the opinion about the importance for protective functions both ERǂ (Gerard’es et 
al, 2006; Pare at al., 2002), and ERǃ (Watanabe et al., 2003). It is impossible to note the 
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experimental data, showing the cardioprotective activity of estrogens, which is not mediated 
by nuclear receptors (Shavva et al., 1987; Karas et al., 2001). 
Estrogens increase vasodilatation and inhibit the response of blood vessels to injury and the 
development of atherosclerosis, this action is referred to non genomic, this develops 
maximum after 20 min after estrogen introduction (Mendelsohn & Karas, 1999). Fast 
vasodilatation is possible due to the influence on both calcium-activated potassium ion-
channel function (Ghanam et al., 2000), and on the synthesis of nitric oxide (the last relaxes 
vascular smooth muscle and inhibits platelet activation (Holm et al., 1997; Node et al., 
1997). More detailed ways of non-genomic effects have been considered by Mendelsohn & 
Karas (1999).   
Of crucial importance is the influence of agents on hemodynamic functions (Borissoff et al., 
2011). 
One more factor of risk of arising of atherosclerosis and thrombosis is higher content of 
oxidized lipoproteins, possible mechanism of these diseases have been considered 
(Steinberg et al., 1989; Holvoet & Collen, 1994). 
Antioxidant action of estrogens has been widely studied in vivo and in vitro. Besides its 
effects on LDL-oxidation (Maziere et al., 1991; Markides et al., 1998; Ruiz-Larrea et al., 
2000; Badeau et al., 2005), it has reported that estrogens decreased lipid peroxidation in 
brain homogenates and neuronal cultures (Vedder et al., 1999; Thibodeau P. et al., 2002), 
reduced the superoxide anion production of different cells (Bekesi et al., 2000; Florian et al., 
2004). All these effects may contribute to the beneficial consequences of estrogen 
replacement on the cardiac and vascular function, bone and mineral metabolism, brain 
function.      
In the experiments on rabbits with hypercholesterinemic diet it was shown that 17-
dihydroequilin sulphate and 17-ethynylestradiol significantly reduce atherosclerosis by 
35% in the aortic arch and 75-80% in the thoracic and abdominal aorta, in spite of high level 
of LDL cholesterol (Sulistiany at al., 1995). High ration between HDL and LDL level is 
important but is not absolute parameter in prognosis of cardio-heart diseases risk. Clinical 
trials of estrone sulphate (at the same time 17-ethynylestradiol has been investigated) in 
postmenopausal women have shown the significant improvement of this parameter. It is 
important that the action of estrone sulphate did not result in triglycerides level increasing 
in contrast to 17-ethynylestradiol (Colvin et al., 1990).   
Thus, numerous investigations on animal models (we described only few of them) give the 
evidence about the advisability of application of estrogens for HRT. First clinical trials for 
using of estrogens with this aim gave optimism, however wide-ranging investigations did 
not confirm the expectations. In older postmenopausal women with established coronary-
artery atherosclerosis, 17ǃ-estradiol had no significant effect on the progression of 
atherosclerosis (Hodis et al., 2003). Moreover, the combination: estrogen plus progestin may 
increase the risk of CHD (Manson et al., 2003). This is very important effect, because the 
content of triglycerides in blood is the independent factor of risk of cardio-vascular diseases 
(Koren et al., 1996). 
This difference is very important because the increased level of triglycerides in blood is the 
independent factor of risk of cardiovascular diseases (Koren et al., 1996). 
From other side, main and side effects of any medication depend on/from methods of the 
introduction into the body. Therefore the positive results obtained during transdermal 
introduction of estradiol takes attention (Sumino et. al., 2006). Oral estrogens raised 
triglycerides whilst transdermal estradiol lowered those (Nerbrand et al., 2004). The 
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conclusion about propriety of such introduction of estrogens may be done only after wide-
ranging long-term investigations.  
The investigations of influence of estrogen receptors modulators, being already in clinical 
application, on coronary heart system have particular interest. First of them is raloxifen. 
Raloxifene blocks the sedimentation of redundant cholesterol in aorta in the experiments on 
rabbits (Bjarnason et al., 1997; 2001).    
One more new steroid has interesting properties (Pelzer et al., 2005), this analogue in the 
experiments in estrogen-deficient spontaneously hypertensive rats has positive influence on 
hemodynamic function and inhibits cardiac hypertrophy.  
8. Conclusion  
From the data presented it became obviously the strategy for the searching of new 
medications on the basis of estrogen receptors ligands with the improved properties in 
comparison with clinically used. As far as the synthesis of such ligand is very complicated 
task, on the first stage the group with known structure peculiarities in the solution 
(including conformational dynamics) and determinate the possibilities for theoretical 
calculations of their spatial structure. The following docking of new possible agents into 
structures of macromolecule compounds (receptors, enzymes and other proteins) is used for 
the selection of most perspective compounds. And it is quite necessary to take into account 
the metabolic ways of new analogues.  
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occurring or synthetic fat-soluble organic compounds. They are found in plants, animals, and fungi. They
mediate a very diverse set of biological responses. The most widespread steroid in the body is cholesterol, an
essential component of cell membranes, and the starting point for the synthesis of other steroids. Since the
science of steroids has an enormous scope, we decided to put the clinical aspects of steroids in a different
book titled "Steroids-Clinical Aspects". The two books complete each other. We hope that the reader will gain
valuable information from both books and enrich their knowledge about this fascinating topic.
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